Related Experiment Videos
Postmastectomy locally recurrent breast cancer
L J Humphrey1, D L Moore, G H Lytle
1Department of Surgery, Oral Roberts School of Medicine, Tulsa, Oklahoma.
Journal of Surgical Oncology
|February 1, 1990
Summary
This study compares local recurrence rates after modified radical mastectomy (MRM) with adjuvant immunotherapy (IT) to historical data. It also reports on risk factors and treatments for post-mastectomy breast cancer recurrence.
Area of Science:
- Oncology
- Breast Cancer Research
- Surgical Oncology
Background:
- Distinguishing ipsilateral breast recurrence from local recurrence after mastectomy is crucial with breast-conserving surgery popularity.
- Modified radical mastectomy (MRM) is a common treatment for breast cancer.
- Understanding local recurrence patterns post-MRM is vital for patient management.
Purpose of the Study:
- To compare the incidence of locally recurrent breast cancer after MRM with adjuvant immunotherapy (IT) against historical controls.
- To identify risk factors associated with local recurrence following MRM.
- To report on treatment strategies for local recurrence in patients who underwent MRM.
Main Methods:
- Retrospective analysis of patients with skin or chest wall recurrence after MRM.
- Comparison of recurrence rates in patients receiving adjuvant immunotherapy (IT) versus historical control groups.
- Evaluation of risk factors and treatment outcomes for local recurrence.
Main Results:
- Incidence of post-MRM local recurrence with adjuvant IT is compared to historical data.
- Key risk factors for local recurrence after MRM are identified.
- Treatment outcomes for local recurrence in a cohort of post-MRM patients are presented.
Conclusions:
- The study provides insights into the natural history of local recurrence after MRM, particularly with adjuvant immunotherapy.
- Findings contribute to understanding risk factors and optimizing treatment for post-mastectomy breast cancer recurrence.
- This research aids in refining management strategies for breast cancer patients undergoing MRM.